Short Interest in Lyell Immunopharma, Inc. (NASDAQ:LYEL) Decreases By 19.4%

Lyell Immunopharma, Inc. (NASDAQ:LYEL) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 10,660,000 shares, a drop of 19.4% from the September 15th total of 13,220,000 shares. Based on an average daily trading volume, of 667,100 shares, the days-to-cover ratio is presently 16.0 days. Currently, 9.4% of the company’s shares are sold short.

Hedge Funds Weigh In On Lyell Immunopharma

Several hedge funds and other institutional investors have recently modified their holdings of LYEL. Opaleye Management Inc. bought a new stake in Lyell Immunopharma during the 1st quarter valued at approximately $7,482,000. Caxton Associates LP grew its stake in Lyell Immunopharma by 359.1% in the first quarter. Caxton Associates LP now owns 174,657 shares of the company’s stock worth $389,000 after purchasing an additional 136,611 shares during the period. Invenomic Capital Management LP boosted its holdings in shares of Lyell Immunopharma by 16.8% during the 1st quarter. Invenomic Capital Management LP now owns 871,525 shares of the company’s stock valued at $1,944,000 after buying an additional 125,110 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Lyell Immunopharma by 1.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,731,477 shares of the company’s stock worth $15,013,000 after purchasing an additional 92,594 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of Lyell Immunopharma in the 1st quarter worth about $191,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently weighed in on LYEL. Bank of America dropped their target price on Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating for the company in a report on Thursday, June 27th. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Monday, August 19th.

Lyell Immunopharma Price Performance

LYEL traded down $0.02 during midday trading on Tuesday, reaching $1.17. 315,118 shares of the company’s stock traded hands, compared to its average volume of 895,586. Lyell Immunopharma has a 52 week low of $1.06 and a 52 week high of $3.26. The firm has a fifty day moving average of $1.33 and a two-hundred day moving average of $1.86. The stock has a market capitalization of $298.28 million, a price-to-earnings ratio of -1.30 and a beta of -0.53.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.02. The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. Sell-side analysts forecast that Lyell Immunopharma will post -0.85 EPS for the current year.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.